Editas Medicine (EDIT) Long-Term Debt Repayments (2015 - 2025)

Editas Medicine (EDIT) reported Long-Term Debt Repayments of $2.9 million for Q1 2025, up 1116.95% quarter-over-quarter from $236000.0 in Q4 2018.

Editas Medicine (EDIT) Long-Term Debt Repayments (2015 - 2025) Analysis & Trends

Editas Medicine (EDIT) has 4 years of Long-Term Debt Repayments data on file, last reported at $2.9 million in Q1 2025.

Long-Term Debt Repayments for Q1 2025 came in at $2.9 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $2.9 million (up 1116.95% YoY), and the FY2018 annual result was $857000.0, up 12.17% from the prior year.
Long-Term Debt Repayments rose to $2.9 million in Q1 2025 per EDIT's latest filing, from $236000.0 in the prior quarter.
Over five years, Long-Term Debt Repayments peaked at $2.9 million in Q1 2025 and troughed at $2.9 million in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-21,671.00
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Editas Medicine	262.77 Mn	262.77 Mn	-	-

Download Data